Posttreatment Imaging in Patients with Head and Neck Cancer without Clinical Evidence of Recurrence: Should Surveillance Imaging Extend Beyond 6 Months?
- 18 June 2020
- journal article
- research article
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 41 (7) , 1238-1244
Abstract
BACKGROUND AND PURPOSE: Early detection of residual or recurrent disease is important for effective salvage treatment in patients with head and neck cancer. Current National Comprehensive Cancer Network guidelines do not recommend standard surveillance imaging beyond 6 months unless there are worrisome signs or symptoms on clinical examination and offer vague guidelines for imaging of high-risk patients beyond that timeframe. Our goal was to evaluate the frequency of clinically occult recurrence in patients with head and neck squamous cell carcinoma with positive imaging findings (Neck Imaging Reporting and Data Systems scores of 2–4), especially after 6 months. MATERIALS AND METHODS: This institutional review board–approved, retrospective data base search queried neck CT reports with Neck Imaging Reporting and Data Systems scores of 2–4 from June 2014 to March 2018. The electronic medical records were reviewed to determine outcomes of clinical and radiologic follow-up, including symptoms, physical examination findings, pathologic correlation, and clinical notes within 3 months of imaging. RESULTS: A total of 255 cases, all with Neck Imaging Reporting and Data Systems scores of 2 or 3, met the inclusion criteria. Fifty-nine patients (23%) demonstrated recurrence (45 biopsy-proven, 14 based on clinical and imaging progression), and 21 patients (36%) had clinically occult recurrence (ie, no clinical evidence of disease at the time of the imaging examination). The median overall time to radiologically detected, clinically occult recurrence was 11.4 months from treatment completion. CONCLUSIONS: Imaging surveillance beyond the first posttreatment baseline study was critical for detecting clinically occult recurrent disease in patients with head and neck squamous cell carcinoma. More than one-third of all recurrences were seen in patients without clinical evidence of disease; and 81% of clinically occult recurrences occurred beyond 6 months.Keywords
This publication has 29 references indexed in Scilit:
- Predictive Value of First Posttreatment Imaging Using Standardized Reporting in Head and Neck CancerOtolaryngology–Head and Neck Surgery, 2019
- Negative Predictive Value of NI-RADS Category 2 in the First Posttreatment FDG-PET/CT in Head and Neck Squamous Cell CarcinomaAmerican Journal of Neuroradiology, 2018
- ACR Neck Imaging Reporting and Data Systems (NI-RADS): A White Paper of the ACR NI-RADS CommitteeJournal of the American College of Radiology, 2018
- Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell CarcinomaAmerican Journal of Neuroradiology, 2017
- Implementation of a Novel Surveillance Template for Head and Neck Cancer: Neck Imaging Reporting and Data System (NI-RADS)Journal of the American College of Radiology, 2016
- Optimal timing of first posttreatment FDG PET/CT in head and neck squamous cell carcinomaHead & Neck, 2015
- Predictive accuracy of first post‐treatment PET/CT in HPV‐related oropharyngeal squamous cell carcinomaThe Laryngoscope, 2014
- Negative Predictive Value of Surveillance PET/CT in Head and Neck Squamous Cell CancerAmerican Journal of Neuroradiology, 2013
- Temporal patterns of head and neck squamous cell carcinoma recurrence with positron‐emission tomography/computed tomography monitoringThe Laryngoscope, 2012
- A systematic review and meta‐analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapyClinical Otolaryngology, 2008